Clinicopathologic characteristics and survival analysis of 183 cases of triple negative breast cancer
10.3760/cma.j.issn.1007-631X.2012.03.020
- VernacularTitle:183例三阴性乳腺癌临床病理特征及生存分析
- Author:
Ruirui MA
;
Lin CHEN
;
Xin CHEN
;
Xiaoan LIU
;
Xiaoming ZHA
;
Shui WANG
;
Yiqun LIU
;
Aidi TAO
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Receptors,estrogen;
Gene,erbB-2;
Pathology,clinical
- From:
Chinese Journal of General Surgery
2012;27(3):230-233
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinicopathologic characteristics and prognosis of triple negative breast cancer patients. Methods A retrospective analysis was performed for 1042 primary breast cancer patients admitted in the First Affiliated Hospital of Nanjing Medical University from January 2003 to December 2009.All breast cancer patients were categorized into three subgroups by immunohistochemistry:ERBB2 +,HR +/ERBB2 - and triple negative. Results Of 1042 breast cancer patients recruited,183 patients were in triple negative group.The rate of larger tumors ( greater than 2 cm in diameter) and grade Ⅲ in triple negative patients was higher than that in ERBB2 + and HR +/ERBB2 - patients (P ＜0.01 ).The positive rate of p53 status in ERBB2 + patients was higher than that in triple negative and HR +/ERBB2- patients (P ＜ 0.01 ).No significant differences were observed in other clinical variables.In survival analysis,more bone metastases were observed in HR +/ERBB2 - patients than in ERBB2 + and triple negative patients (P =0.006).However,no significant difference was observed in visceral metastases among the subgroups.There were significantly different recurrence-free survivals (RFS) among the three subgroups throughout the follow-up period ( P =0.029),the 5-year RFS of ERBB2 + was 80.3％,which was the worst in three groups. Conclusions Triple negative patients had higher rate of larger tumors (greater than 2 cm in diameter) and grade Ⅲ than that in ERBB2 + and HR +/ERBB2 - patients,while its 5-year RFS was higher than ERBB2 + patients.
